Linzagolix
CAS: 935283-04-8
Ref. TM-T27837
| 1mg | 52.00 € | ||
| 5mg | 94.00 € | ||
| 10mg | 157.00 € | ||
| 25mg | 297.00 € | ||
| 50mg | 537.00 € | ||
| 1ml*10 (DMSO) | 113.00 € |
Estimated delivery in United States, on Wednesday 22 May 2024
Product Information
Name:
Linzagolix
CAS:
Description:
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
508.42
Formula:
C22H15F3N2O7S
Purity:
99.68%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T27837 Linzagolix
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
